share_log

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79

Benzinga ·  May 8 12:55

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $80 to $79.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment